Aegerion Pharmaceuticals, Inc.
101 Main Street
Suite 1850
Cambridge
Massachusetts
02142
United States
Tel: 617-500-7867
Fax: 908-541-1155
Website: http://www.aegerion.com/
Email: info@aegerion.com
219 articles about Aegerion Pharmaceuticals, Inc.
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
9/9/2014
-
Aegerion Pharmaceuticals, Inc. To Present At The Morgan Stanley Global Healthcare Conference
9/4/2014
-
Aegerion Pharmaceuticals, Inc. Announces Resolution Of Warning Letter For JUXTAPID® (Lomitapide) Capsules
8/27/2014
-
Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes Offering
8/12/2014
-
Aegerion Pharmaceuticals, Inc. Announces Intention To Offer $250 Million Of Convertible Notes
8/11/2014
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
8/8/2014
-
Aegerion Pharmaceuticals, Inc. Appoints Craig Fraser As Chief Operating Officer
7/30/2014
-
Aegerion Pharmaceuticals, Inc. Announces Second-Quarter 2014 Financial Results
7/30/2014
-
Aegerion Pharmaceuticals, Inc.To Announce Second Quarter 2014 Financial Results On Tuesday, July 29
7/22/2014
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
7/9/2014
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
6/6/2014
-
Aegerion Pharmaceuticals, Inc. Announces Presentation At The Jefferies and Co. 2014 Global Healthcare Conference
5/28/2014
-
Boston CEO Conference To Feature Ceos Of Aegerion Pharmaceuticals, Inc., Alkermes plc, Alnylam Pharmaceuticals, Flex Pharma, Genzyme Corporation, Infinity Pharmaceuticals Inc., OvaScience, Sarepta Therapeutics, Tesaro, Inc., Verastem, Inc. And Others June
5/20/2014
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
5/8/2014
-
Aegerion Pharmaceuticals, Inc. Announces First-Quarter 2014 Financial Results
5/7/2014
-
Aegerion Pharmaceuticals, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences
5/1/2014
-
Aegerion Pharmaceuticals, Inc. To Announce First Quarter 2014 Financial Results On Tuesday, May 6
4/30/2014
-
Aegerion Pharmaceuticals, Inc. Initiates Phase 3 Clinical Trial In Japan To Evaluate Lomitapide For Treatment Of Homozygous Familial Hypercholesterolemia (Hofh)
4/9/2014
-
Aegerion Pharmaceuticals, Inc. Grants Stock Options Under Inducement Program
4/8/2014
-
Aegerion Pharmaceuticals, Inc. Warns Of Negative Impact Of DOJ Investigation
3/6/2014